Date | Title | Description | |
---|---|---|---|
02 Mar 2021 | On business and financial situation | The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
Date | Title | Description | |
---|---|---|---|
25 Feb 2025 | Annual Financial Reports and Audit Reports | The Company submits the 2024 Annual Financial Report | Download |
25 Feb 2025 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2024 annual report regarding remuneration of the members of the Board of Directors | Download |
07 Jan 2025 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the fourth quarter of 2024 | Download |
07 Nov 2024 | On P&L | A correction to the English version of a document is reported. | Download |
03 Oct 2024 | Liquidity and counterparty agreements | Liquidity contract: transactions conducted in the third quarter of 2024 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
06 Nov 2018 | Información sobre resultados | ROVI releases the presentation related to the nine-month period ended 30 September 2018 results. | Download |
06 Nov 2018 | Información sobre resultados | ROVI releases the press release related to the nine-month period ended 30 September 2018 results. | Download |
17 Oct 2018 | Buy-back programmes, stabilisation and treasury stock | ROVI informs of the resumption of operations with own shares under the liquidity contract | Download |
17 Oct 2018 | Buy-back programmes, stabilisation and treasury stock | ROVI informs that Jefferies International Limited has exercised, in full, the greenshoe subscription option | Download |
08 Oct 2018 | Share capital increases and reductions | Information on new shares admissions related to the capital increase of ROVI | Download |